NCT01597635 - The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2012

Primary Completion Date

October 1, 2014

Study Completion Date

October 6, 2014

Conditions

Lung Injury, Acute

Interventions

DRUG

Dose 1 GSK2586881

Low dose GSK2586881 administered intravenously

DRUG

Dose 2 GSK2586881

Medium dose GSK2586881 administered intravenously

DRUG

Dose 3 GSK2586881

Medium-High dose GSK2586881 administered intravenously

DRUG

Dose 4 GSK2586881

High dose GSK2586881 administered intravenously

DRUG

Placebo (saline)

Administered intravenously to match intervention

Trial Locations (19)

10003

GSK Investigational Site, New York

19104

GSK Investigational Site, Philadelphia

19107

GSK Investigational Site, Philadelphia

27403

GSK Investigational Site, Greensboro

27517

GSK Investigational Site, Winston-Salem

27710

GSK Investigational Site, Durham

29425

GSK Investigational Site, Charleston

43215

GSK Investigational Site, Columbus

48109

GSK Investigational Site, Ann Arbor

60611

GSK Investigational Site, Chicago

95817

GSK Investigational Site, Sacramento

97239

GSK Investigational Site, Portland

01199

GSK Investigational Site, Springfield

V5Z 1M9

GSK Investigational Site, Vancouver

V6Z 1Y6

GSK Investigational Site, Vancouver

B3H 2Y9

GSK Investigational Site, Halifax

K7L 2V7

GSK Investigational Site, Kingston

J4V 2H1

GSK Investigational Site, Greenfield Park

G1V 4G5

GSK Investigational Site, Sainte-Foy